{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:24:10Z","timestamp":1793651050532,"version":"4.5.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1530"],"award-info":[{"award-number":["SFB1530"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1530"],"award-info":[{"award-number":["SFB1530"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1530"],"award-info":[{"award-number":["SFB1530"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1530"],"award-info":[{"award-number":["SFB1530"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1530"],"award-info":[{"award-number":["SFB1530"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1530"],"award-info":[{"award-number":["SFB1530"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1530"],"award-info":[{"award-number":["SFB1530"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diffuse large B-cell lymphoma (DLBCL) exhibits marked clinical heterogeneity and frequent treatment resistance, particularly in molecularly defined high-risk subtypes such as ABC-DLBCL. While current therapies largely rely on apoptosis induction, non-apoptotic cell death pathways remain underexplored in hematologic malignancies. Here, we identify ferroptosis, an iron-dependent, lipid peroxidation-driven form of regulated necrosis, as an effective baseline in additive therapy with ibrutinib for the treatment of DLBCL. Transcriptomic and lipidomic analyses revealed that DLBCL cells, despite lacking overt enrichment of polyunsaturated fatty acids (PUFAs), display elevated expression of the core ferroptosis protective machinery. Inhibition of GPX4 induced rapid and selective lipid ROS accumulation and cell death across a panel of human and murine DLBCL cellular models irrespective of subtype. Notably, the BTK inhibitor and clinical compound ibrutinib showed additive effects with GPX4 inhibition, even at concentrations below its cytotoxic threshold, expanding its therapeutic relevance beyond BTK inhibition. Mechanistically, we uncover two activities of ibrutinib to enhance ferroptosis sensitivity: First, chemical scavenging of glutathione and second the inhibition of GPX4 protein expression via translational repression. Thereby, our findings define ferroptosis as a basis for additive therapy in combination with ibrutinib in DLBCL and reveal a previously unrecognized role for ibrutinib in directly modulating anti-oxidant defense.<\/jats:p>","DOI":"10.1038\/s41420-025-02826-w","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:23:51Z","timestamp":1761917031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Redox destabilization by ibrutinib promotes ferroptosis in diffuse large B-cell lymphoma (DLBCL)"],"prefix":"10.1038","volume":"11","author":[{"given":"Anuschka","family":"Langpape","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Bonasera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Stroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4160-7664","authenticated-orcid":false,"given":"Moritz","family":"Reese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cartolano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmaria","family":"Liccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7816-5919","authenticated-orcid":false,"given":"Silvia","family":"von Karstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2826_CR1","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","volume":"16","author":"Y Miao","year":"2019","unstructured":"Miao Y, Medeiros LJ, Li Y, Li J, Young KH. Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019;16:634\u201352.","journal-title":"Nat Rev Clin Oncol"},{"key":"2826_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311.","journal-title":"Nature"},{"key":"2826_CR3","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313\u201323.","journal-title":"N Engl J Med"},{"key":"2826_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"2826_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","volume":"560","author":"JD Phelan","year":"2018","unstructured":"Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018;560:387\u201391.","journal-title":"Nature"},{"key":"2826_CR6","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","volume":"111","author":"LT Lam","year":"2008","unstructured":"Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111:3701\u201313.","journal-title":"Blood"},{"key":"2826_CR7","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.3390\/cancers13092167","volume":"13","author":"E Leveille","year":"2021","unstructured":"Leveille E, Johnson NA. Genetic events inhibiting apoptosis in diffuse large B cell lymphoma. Cancers (Basel). 2021;13:2167.","journal-title":"Cancers (Basel)"},{"key":"2826_CR8","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","volume":"39","author":"WH Wilson","year":"2021","unstructured":"Wilson WH, Wright G, Huang DW, Hodkinson B, Balasubramanian S, Fan Y, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39:1643\u2013.e3.","journal-title":"Cancer Cell"},{"key":"2826_CR9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood.2020006578","volume":"137","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Ill\u00e9s \u00c1, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137:600\u20139.","journal-title":"Blood"},{"key":"2826_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551:247\u201350.","journal-title":"Nature"},{"key":"2826_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547:453\u20137.","journal-title":"Nature"},{"key":"2826_CR12","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell"},{"key":"2826_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317\u201331.","journal-title":"Cell"},{"key":"2826_CR14","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/ncb3064","volume":"16","author":"JPF Angeli","year":"2014","unstructured":"Angeli JPF, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16:1180\u201391.","journal-title":"Nat Cell Biol"},{"key":"2826_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s41589-019-0408-1","volume":"15","author":"M Conrad","year":"2019","unstructured":"Conrad M, Pratt DA. The chemical basis of ferroptosis. Nat Chem Biol. 2019;15:1137\u201347.","journal-title":"Nat Chem Biol"},{"key":"2826_CR16","doi-asserted-by":"crossref","unstructured":"Bersuker K, Hendricks J, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 2019:575;688\u201392.","DOI":"10.1038\/s41586-019-1705-2"},{"key":"2826_CR17","first-page":"1060","volume":"149","author":"Doll","year":"2019","unstructured":"Doll, Freitas S, Shah FP, Aldrovandi R, Silva M, da MC, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;149:1060\u201320.","journal-title":"Nature"},{"key":"2826_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nchembio.2238","volume":"13","author":"VE Kagan","year":"2017","unstructured":"Kagan VE, Mao G, Qu F, Angeli JPF, Doll S, Croix CS, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13:81\u201390.","journal-title":"Nat Chem Biol"},{"key":"2826_CR19","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/s41419-020-03118-0","volume":"11","author":"B Wiernicki","year":"2020","unstructured":"Wiernicki B, Dubois H, Tyurina YY, Hassannia B, Bayir H, Kagan VE, et al. Excessive phospholipid peroxidation distinguishes ferroptosis from other cell death modes including pyroptosis. Cell Death Dis. 2020;11:922\u201311.","journal-title":"Cell Death Dis"},{"key":"2826_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13:91\u201398.","journal-title":"Nat Chem Biol"},{"key":"2826_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116386","volume":"173","author":"W Bian","year":"2024","unstructured":"Bian W, Li H, Chen Y, Yu Y, Lei G, Yang X, et al. Ferroptosis mechanisms and its novel potential therapeutic targets for DLBCL. Biomed Pharmacother. 2024;173:116386.","journal-title":"Biomed Pharmacother"},{"key":"2826_CR22","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1182\/blood.2020009404","volume":"138","author":"A Schmitt","year":"2021","unstructured":"Schmitt A, Xu W, Bucher P, Grimm M, Konantz M, Horn H, et al. Dimethyl fumarate induces ferroptosis and impairs NF-\u03baB\/STAT3 signaling in DLBCL. Blood. 2021;138:871\u201384.","journal-title":"Blood"},{"key":"2826_CR23","doi-asserted-by":"publisher","first-page":"7433","DOI":"10.1182\/bloodadvances.2023010964","volume":"7","author":"B Gomez Solsona","year":"2023","unstructured":"Gomez Solsona B, Horn H, Schmitt A, Xu W, Bucher P, Heinrich A, et al. Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress. Blood Adv. 2023;7:7433\u201344.","journal-title":"Blood Adv"},{"key":"2826_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07001-0","volume":"15","author":"S Zhang","year":"2024","unstructured":"Zhang S, Wang J, Huang G, Xiao X, Xu S, Weng P, et al. TCP1 expression alters the ferroptosis sensitivity of diffuse large B-cell lymphoma subtypes by stabilising ACSL4 and influences patient prognosis. Cell Death Dis. 2024;15:611.","journal-title":"Cell Death Dis"},{"key":"2826_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/cancers12010164","volume":"12","author":"CM Bebber","year":"2020","unstructured":"Bebber CM, M\u00fcller F, Clemente LP, Weber J, von Karstedt S. Ferroptosis in cancer cell biology. Cancers. 2020;12:164.","journal-title":"Cancers"},{"key":"2826_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13649","author":"FI Yapici","year":"2024","unstructured":"Yapici FI, Bebber CM, von Karstedt S. A guide to ferroptosis in cancer. Mol Oncol. 2024. https:\/\/doi.org\/10.1002\/1878-0261.13649.","journal-title":"Mol Oncol"},{"key":"2826_CR27","first-page":"348","volume":"15","author":"JPF Angeli","year":"2019","unstructured":"Angeli JPF, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019;15:348.","journal-title":"Nat Rev Cancer"},{"key":"2826_CR28","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia B, Vandenabeele P, Berghe TV. Targeting ferroptosis to iron out cancer. Cancer cell. 2019;35:830\u201349.","journal-title":"Cancer cell"},{"key":"2826_CR29","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell. 2017;170:564\u201376.e16.","journal-title":"Cell"},{"key":"2826_CR30","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1038\/s41467-021-22336-4","volume":"12","author":"CM Bebber","year":"2021","unstructured":"Bebber CM, Thomas ES, Stroh J, Chen Z, Androulidaki A, Schmitt A, et al. Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes. Nat Commun. 2021;12:2048\u201319.","journal-title":"Nat Commun"},{"key":"2826_CR31","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.1038\/s41467-020-20154-8","volume":"11","author":"E Dai","year":"2020","unstructured":"Dai E, Han L, Liu J, Xie Y, Zeh HJ, Kang R, et al. Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173\/STING-dependent DNA sensor pathway. Nat Commun. 2020;11:6339\u201311.","journal-title":"Nat Commun"},{"key":"2826_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/2643-3230.BCD-19-0059","volume":"2","author":"R Fl\u00fcmann","year":"2020","unstructured":"Fl\u00fcmann R, Rehk\u00e4mper T, Nieper P, Pfeiffer P, Holzem A, Klein S, et al. An autochthonous mouse model of Myd88- and BCL2-driven diffuse large B cell lymphoma reveals actionable molecular vulnerabilities. Blood Cancer Discov. 2020;2:70\u201391.","journal-title":"Blood Cancer Discov"},{"key":"2826_CR33","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non\u2013germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:1285\u201395.","journal-title":"J Clin Oncol"},{"key":"2826_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7005","volume":"13","author":"T Deng","year":"2024","unstructured":"Deng T, Zhang S, Xiao M, Gu J, Huang L, Zhou X. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88mut \/CD79Bmut diffuse large B-cell lymphoma. Cancer Med. 2024;13:e7005.","journal-title":"Cancer Med"},{"key":"2826_CR35","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMoa2401532","volume":"390","author":"C Melani","year":"2024","unstructured":"Melani C, Lakhotia R, Pittaluga S, Phelan JD, Huang DW, Wright G, et al. Combination targeted therapy in relapsed diffuse large B-cell lymphoma. N Engl J Med. 2024;390:2143\u201355.","journal-title":"N Engl J Med"},{"key":"2826_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/484537","volume":"2015","author":"F Turturro","year":"2015","unstructured":"Turturro F. Constitutive NF-\u03baB activation underlines major mechanism of drug resistance in relapsed refractory diffuse large B cell lymphoma. Biomed Res Int. 2015;2015:484537.","journal-title":"Biomed Res Int"},{"key":"2826_CR37","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.18632\/aging.101121","volume":"8","author":"M Zhang","year":"2016","unstructured":"Zhang M, Xu-Monette ZY, Li L, Manyam GC, Visco C, Tzankov A, et al. RelA NF-\u03baB subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging (Albany NY). 2016;8:3321\u201340.","journal-title":"Aging (Albany NY)"},{"key":"2826_CR38","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2023.12.019","volume":"42","author":"JD Phelan","year":"2024","unstructured":"Phelan JD, Scheich S, Choi J, Wright GW, H\u00e4upl B, Young RM, et al. Response to Bruton\u2019s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. Cancer Cell. 2024;42:238\u201352.e9.","journal-title":"Cancer Cell"},{"key":"2826_CR39","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1182\/blood.2022019274","volume":"142","author":"A Schmitt","year":"2023","unstructured":"Schmitt A, Grimm M, Kreienkamp N, Junge H, Labisch J, Schuhknecht L, et al. BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis. Blood. 2023;142:1143\u201355.","journal-title":"Blood"},{"key":"2826_CR40","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.chembiol.2018.11.016","volume":"26","author":"L Magtanong","year":"2019","unstructured":"Magtanong L, Ko P-J, To M, Cao JY, Forcina GC, Tarangelo A, et al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. Cell Chem Biol. 2019;26:420\u201332.e9.","journal-title":"Cell Chem Biol"},{"key":"2826_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10637-020-00970-x","volume":"39","author":"JJM Rood","year":"2021","unstructured":"Rood JJM, Jamalpoor A, van Hoppe S, van Haren MJ, Wasmann RE, Janssen MJ, et al. Extrahepatic metabolism of ibrutinib. Invest N Drugs. 2021;39:1\u201314.","journal-title":"Invest N Drugs"},{"key":"2826_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/0886022X.2021.1874985","volume":"43","author":"C Mark\u00f3th","year":"2021","unstructured":"Mark\u00f3th C, File I, Sz\u00e1sz R, Bidiga L, Balla J, M\u00e1tyus J. Ibrutinib-induced acute kidney injury via interstitial nephritis. Ren Fail. 2021;43:335\u20139.","journal-title":"Ren Fail"},{"key":"2826_CR43","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-15-1191","volume":"22","author":"M Klanova","year":"2016","unstructured":"Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, et al. Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-dependent subgroups of diffuse large B-cell lymphoma. Clin Cancer Res. 2016;22:1138\u201349.","journal-title":"Clin Cancer Res"},{"key":"2826_CR44","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/s41375-025-02533-6","volume":"39","author":"S Glaser","year":"2025","unstructured":"Glaser S, Fischer A, Mart\u00ednez-Manj\u00f3n JE, L\u00f3pez C, Kretzmer H, Burkhardt B, et al. Subgrouping germinal center-derived B-cell lymphomas based on machine learning-deduced DNA methylation modules. Leukemia. 2025;39:967\u201371.","journal-title":"Leukemia"},{"key":"2826_CR45","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739\u2013W743.","journal-title":"Nucleic Acids Res"},{"key":"2826_CR46","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1083\/jcb.201404147","volume":"211","author":"V Kumar","year":"2015","unstructured":"Kumar V, Bouameur JE, B\u00e4r J, Rice RH, Hornig-Do HT, Roop DR, et al. A keratin scaffold regulates epidermal barrier formation, mitochondrial lipid composition, and activity. J Cell Biol. 2015;211:1057\u201375.","journal-title":"J Cell Biol"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02826-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02826-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02826-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T15:02:41Z","timestamp":1761922961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02826-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2826"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02826-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7038817\/v1","asserted-by":"object"}]},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations concerning good scientific practice. Human buffy coats were used for B-cell and PBMC isolation using ethics approval obtained at the University Hospital Cologne (21-1532).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"495"}}